In 2017, the Australian biotech company Zelda completed observational trials in Chile suggesting medical cannabis extracts may be effective for treating the core symptoms of Autism, including difficulties in social interactions, language, and repetitive behaviors. The study involved 21 patients, with the median age around 9 years old, who were treated with medical cannabis extracts over the course 12 weeks. The patients were then examined by EEG, neuropsychological analysis, metabolism, and genetic tests. Of those treated with the extracts, 71.4% showed improvements in at least one of their core symptoms, and 66.7% improved overall. Additionally, cannabis extracts were more effective than the more traditional medications.Since then, Zelda has initiated the recruitment for observational trials in the USA, with 15 patients already formally enrolled for trials beginning this year. They hope this will lead to future clinical trials.